845 related articles for article (PubMed ID: 18387160)
21. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
[TBL] [Abstract][Full Text] [Related]
22. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
[TBL] [Abstract][Full Text] [Related]
23. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
[TBL] [Abstract][Full Text] [Related]
24. Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification.
Tokumoto M; Mizobuchi M; Finch JL; Nakamura H; Martin DR; Slatopolsky E
Am J Nephrol; 2009; 29(6):582-91. PubMed ID: 19145073
[TBL] [Abstract][Full Text] [Related]
25. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.
Koiwa F; Kazama JJ; Tokumoto A; Onoda N; Kato H; Okada T; Nii-Kono T; Fukagawa M; Shigematsu T;
Ther Apher Dial; 2005 Aug; 9(4):336-9. PubMed ID: 16076378
[TBL] [Abstract][Full Text] [Related]
26. Ten-year experience with sevelamer and calcium salts as phosphate binders.
Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
[TBL] [Abstract][Full Text] [Related]
27. Sevelamer carbonate.
Barna MM; Kapoian T; O'Mara NB
Ann Pharmacother; 2010 Jan; 44(1):127-34. PubMed ID: 19955298
[TBL] [Abstract][Full Text] [Related]
28. Buffering effects of calcium carbonate as clarified by sevelamer hydrochloride monotherapy.
Akatsuka T; Mochizuki T; Koike T
Ther Apher Dial; 2008 Jun; 12(3):216-25. PubMed ID: 18503699
[TBL] [Abstract][Full Text] [Related]
29. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
Fishbane S; Delmez J; Suki WN; Hariachar SK; Heaton J; Chasan-Taber S; Plone MA; Moe S
Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256
[TBL] [Abstract][Full Text] [Related]
30. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
[TBL] [Abstract][Full Text] [Related]
31. [Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients].
Caravaca F; Ruiz AB; Escola JM; Hernández Gallego R; Cerezo I; Fernández N; Barroso S; Martín MV
Nefrologia; 2007; 27(4):466-71. PubMed ID: 17944584
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
Koizumi M; Fukagawa M
Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
[TBL] [Abstract][Full Text] [Related]
33. Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis.
Chennasamudram SP; Noor T; Vasylyeva TL
J Ren Care; 2013 Jun; 39(2):82-9. PubMed ID: 23574727
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
Ogata H; Koiwa F; Shishido K; Kinugasa E
Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
[TBL] [Abstract][Full Text] [Related]
35. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
[TBL] [Abstract][Full Text] [Related]
36. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
37. Introduction to sevelamer hydrochloride and its clinical effects.
Tahara H; Tsujimoto Y; Shoji T; Inaba M; Tabata T; Nishizawa Y
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S2-6. PubMed ID: 16109137
[TBL] [Abstract][Full Text] [Related]
38. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
Negri AL
J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
[TBL] [Abstract][Full Text] [Related]
39. Sevelamer therapy for pediatric end-stage renal disease.
Storms LE; Chicella MF; Dice JE
Pharmacotherapy; 2006 Mar; 26(3):410-3. PubMed ID: 16503722
[TBL] [Abstract][Full Text] [Related]
40. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
Runowski D; Jachimiak B; Cieślak-Puchalska A; Pacanowska B; Zimoń T
Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
